AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03885479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens
Description: An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
Study NCT03824496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cranial Accelerometry Measurement
Description: Measuring the HeadPulse using cranial accelerometry
Study NCT02880735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ventilation.
Description: Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
Study NCT01003340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wee Wheezers
Description: The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
Study NCT02425969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
Study NCT01276301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: single dose verapamil
Study NCT01276301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: single dose BI 10773
Study NCT01276301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: single dose BI 10773
Study NCT04485832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth care
Description: Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
Study NCT04485832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weekly CAT measurement
Study NCT02936414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
Study NCT02936414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Accept placebo(300 mg/tid)+SGAs monotherapy.
Study NCT04158388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-diet enriched with a higher dose of tryptophan and magnesium
Description: That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
Study NCT04158388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Isocaloric diet
Description: That group eaten isocaloric diet plan based on Mediterranean diet.
Study NCT04158388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: That group received moderate pressure digital manual therapy.
Study NCT04158388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo therapy
Description: That group was treated with a US (in off mode) without conductive gel.
Study NCT01466010 — intervention group
Intervention type: PROCEDURE
Intervention: surgical removal of osteoid osteoma
Description: surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
Study NCT00307437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg
Description: Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Study NCT00307437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (CNTO 1275) 45 mg
Description: Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Study NCT00307437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (CNTO 1275) 90 mg
Description: Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Study NCT00654290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone + Propranolol
Description: Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
Study NCT00654290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone treated 7 days pre-operation to 5 days post CABG
Study NCT00654290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol from 7 days pre-operation to 5 days post CABG
Study NCT02841163 — intervention group
Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study NCT02841163 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
Study NCT02841163 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT02841163 — intervention group
Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT02841163 — intervention group
Intervention type: PROCEDURE
Intervention: Chuna manipulation
Description: Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Study NCT02748811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
Study NCT01879930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100
Study NCT01879930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group
Study NCT00789737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Welchol
Description: Welchol 625mg tablets
Study NCT00789737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02425969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Study NCT00309569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2
Study NCT00309569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 40mg/m2
Study NCT00309569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2
Study NCT00309569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubucin 60mg/m2 (only node-positive patients)
Study NCT00309569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT03608449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaires
Description: questionnaire about mental health status during psychotherapy
Study NCT03608449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: questionnaire about mental health status during psychotherapy
Study NCT03069859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA (1g)
Description: 1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study NCT01626443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol + D-chiro-inositol + Folic acid
Description: Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
Study NCT01626443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Folic acid (200 mcg); 2 x die
Study NCT03069859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline)
Description: 0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
Study NCT03002675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: exenatide (Bydureon) 2mg s.c. 1x/wk
Study NCT02563223 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02563223 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Subject Loading System
Description: a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
Study NCT03582540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-guidewire cannulation technique
Description: With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
Study NCT00415402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT03426800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and training
Description: Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
Study NCT03779802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device programming of ABBOTT CRT pacemaker or defibrillator
Description: Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
Study NCT00786682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00786682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Study NCT01331915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theravac
Description: Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously.
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00036738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO
Study NCT00036738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation
Study NCT00036738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplantation
Study NCT00036738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Given IV
Study NCT00036738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04650360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Intervention Educational Program
Description: The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
Study NCT00724399 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey on womens health Issues.
Description: Cardiovascular health.
Study NCT03471559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: single or multiple dosing
Study NCT03471559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: single or multiple dosing
Study NCT01521169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).
Description: 1 = Intervention with test product 1 (0,8g of plant sterol/day)
Study NCT01521169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).
Description: 2 = Intervention with test product 2 (1,6g of plant sterol/day)
Study NCT01521169 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 3 - low-fat dairy fermented product (drinkable) without plant sterols.
Description: 3 = Intervention 3 (1 control product/day)
Study NCT04852315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Study NCT04852315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Study NCT01894074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Dietary Intervention
Description: Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
Study NCT02425969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Study NCT02728206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT02194452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gallium Ga 68-edotreotide
Description: Undergo gallium Ga 68-edotreotide PET/CT
Study NCT02194452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT
Study NCT02194452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT
Study NCT02194452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00617162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation, Libra Deep Brain Stimulation System
Description: DBS Active Treatment Group - implanted with investigational device and activated for stimulation
Study NCT00617162 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep Brain Stimulation, Libra Deep Brain Stimulation System
Description: implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
Study NCT01955785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilator
Study NCT01955785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Regulated Volume Controlled Ventilator
Study NCT01633528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asprin
Description: 100 mg
Study NCT01633528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg
Study NCT03908931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Follow up of osteochondral surgery by MRI and clinical examination
Study NCT03209986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation via peripheral vein
Description: 1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
Study NCT03151811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Intravenous infusion